Cbay stock forecast.

Nov 24, 2023 · Stock analysis for Cymabay Therapeutics Inc (CBAY:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Stock Price Forecast. The 7 analysts offering 12-month price forecasts for Verastem Inc have a median target of 32.00, with a high estimate of 36.00 and a low estimate of 17.50. The median ...Nov 28, 2023 · CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary ... Dec 1, 2023 · The consensus price target of analysts on Wall Street is $24.42, which implies an increase of 21.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $34.00 respectively. As a result, CBAY is trading at a discount of -77.73% off the target high and -4.55% off the low.

American ingenuity has lengthy been the driving power behind the US financial system, and few sectors embody this higher than biotech. With over 500 biotech companies working within the US, creating new medical applied sciences, drug therapies, surgical devices, and methods – the record is barely restricted by creativeness.NextPlay Technologies, Inc. (NASDAQ:NXTP) announced its quarterly earnings results on Wednesday, January, 12th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02. The firm earned $4.20 million during the quarter, compared to the consensus estimate of $5.70 …

NextPlay Technologies, Inc. (NASDAQ:NXTP) announced its quarterly earnings results on Wednesday, January, 12th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02. The firm earned $4.20 million during the quarter, compared to the consensus estimate of $5.70 …Their ZOM share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 3,421.1% from the stock's current price. View analysts price targets for ZOM or view top-rated stocks among Wall Street analysts.

September 8, 2023 at 1:12 PM · 3 min read. Shares of clinical-stage biopharmaceutical company CymaBay Therapeutics, Inc. CBAY gained after it announced positive top-line results from its late ...The average Guardforce Ai Co stock price prediction forecasts a potential upside of 260.82% from the current GFAI share price of $3.88. What is GFAI's forecast return on assets (ROA) for 2023-2026? (NASDAQ: GFAI) forecast ROA is N/A, which is lower than the forecast US Security & Protection Services industry average of N/A.See the latest CymaBay Therapeutics Inc stock price (CBAY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Stock Price Forecast The 1 analysts offering 12-month price forecasts for Creative Medical Technology Holdings Inc have a median target of 30.00, with a high estimate of 30.00 and a low estimate ...Analyst Forecast. According to 12 analysts, the average rating for CBAY stock is "Strong Buy." The 12-month stock price forecast is $22.64, which is an increase of 18.35% from the latest price.

Find real-time VSTM - Verastem Inc stock quotes, company profile, news and forecasts from CNN Business.

Weather forecasts play an essential role in our daily lives, helping us plan our activities and stay prepared for any weather conditions that may come our way. One of the most common types of forecasts is the 7-day weather forecast, which p...

The current average CBAY price target, as estimated by these analysts, is $0.00. The predictions for the future CBAY stock price range from a low of $0.00 to a high of $0.00, highlighting the variability of market expectations for CBAY. Find the latest CymaBay Therapeutics, Inc. (CBAY) stock quote, history, news and other vital information to help you with your stock trading and investing. Wall Street Stock Market & Finance report, prediction for the future: You'll find the CBAK Energy Technology share forecasts, stock quote and buy / sell signals below. According to present data CBAK Energy Technology's CBAT shares and potentially its market environment have been in bearish cycle last 12 months (if exists).1,785.90 +6.50(+0.37%) Crude Oil (+0.21%) Advertisement CymaBay Therapeutics, Inc. (CBAY) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M …In this article, we answer “what is sales forecasting?” by breaking down its objectives, owners, methods, and best practices. Sales | What is REVIEWED BY: Jess Pingrey Jess served on the founding team of a successful B2B startup and has use...PTC Therapeutics Inc. -3.71%. $1.57B. CBAY | Complete CymaBay Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

16 brokerages have issued 1-year price targets for Exelixis' stock. Their EXEL share price targets range from $18.00 to $32.00. On average, they expect the company's stock price to reach $25.44 in the next twelve months. This suggests a possible upside of 19.6% from the stock's current price. View analysts price targets for EXEL or view top ...Nov 21, 2023 · According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecasts Find the latest Allarity Therapeutics, Inc. (ALLR) stock quote, history, news and other vital information to help you with your stock trading and investing.CBAY Stock Forecast: Positive Outlook and Analyst Consensus for CymaBay Therapeutics Inc. CBAY stock has been performing well in recent months, with positive forecasts from analysts. On June 30, 2023, the 10 analysts offering 12-month price forecasts for CBAY had a median target of $15.00, indicating a potential increase of …Their ZOM share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 3,421.1% from the stock's current price. View analysts price targets for ZOM or view top-rated stocks among Wall Street analysts.

Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Verastem Inc have a median target of 33.00, with a high estimate of 36.00 and a low estimate of 17.50. The median ...

provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their research and their ... (See CBAY stock forecast on TipRanks) AbSci Corporation . For the second penny stock we’ll look at, we’ll stick with the medical tech field – but look at a company with a different take on ...View Tecnoglass Inc TGLS investment & stock information. Get the latest Tecnoglass Inc TGLS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Nov 6, 2023 · CBAY stock has been performing well according to 12 analysts offering 12-month price forecasts. The median target price is $22.50, with a high estimate of $33.00 and a low estimate of $19.00. This indicates a potential increase of 37.95% from the last recorded price of $16.31. The consensus among 13 polled investment analysts is to buy stock in ... Stock Price Forecast The 8 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 11.00, with a high estimate of. ... What is The target price for CBAY? The 8 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 11.00, with a high estimate of 14.00 and a low …Analyst Forecast According to 10 analysts, the average rating for BMEA stock is "Strong Buy." The 12-month stock price forecast is $47.7, which is an increase of 185.97% from the latest price.ACIU Stock 12 Months Forecast. Based on 2 Wall Street analysts offering 12 month price targets for AC Immune SA in the last 3 months. The average price target is $16.00 with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 417.80% change from the last price of $3.09.

Nov 14, 2023 · CymaBay Therapeutics Stock Forecast 2023. In the last five quarters, CymaBay Therapeutics’s Price Target has fallen from $29.28 to $23.09 - a -21.14% decrease. Five analysts predict that CymaBay Therapeutics’s share price will fall in the coming year, reaching $10.00. This would represent a decrease of -56.69%.

Analyst Price Forecast Suggests 15.86% Upside As of August 2, 2023, the average one-year price target for Cymabay Therapeutics is 15.61. The forecasts range from a low of 12.12 to a high of $19.95.

According to the issued ratings of 7 analysts in the last year, the consensus rating for Verastem stock is Buy based on the current 7 buy ratings for VSTM. The average twelve-month price prediction for Verastem is $29.71 with a high price target of $36.00 and a low price target of $21.00. Learn more on VSTM's analyst rating history.What happened. A significant miss on quarterly earnings combined with a big change in its C-suite put a damper on CymaBay Therapeutics (CBAY 3.03%) stock this week. According to data compiled by S ...Find the latest Cidara Therapeutics, Inc. (CDTX) stock quote, history, news and other vital information to help you with your stock trading and investing.Cymabay Therapeutics (CBAY) Company Description. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral ... CBAY stock has been performing well according to 12 analysts offering 12-month price forecasts. The median target price is $22.50, with a high estimate of $33.00 and a low estimate of $19.00. This indicates a potential increase of 37.95% from the last recorded price of $16.31. The consensus among 13 polled investment analysts is to buy stock in ...The Coterra stock price fell by -1.87% on the last day (Monday, 27th Nov 2023) from $26.77 to $26.27. During the last trading day the stock fluctuated 1.82% from a day low at $26.12 to a day high of $26.59. The price has been going up and down for this period, and there has been a -2.6% loss for the last 2 weeks.CBAY Stock Shows Promising Performance: Analysts Predict 38.63% Increase CBAY stock had a promising performance on November 6, 2023, based on the information provided by CNN Money. The 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc have a median target of 22.50, with a high estimate of 33.00 and a low estimate of 19.00.Stock analysis for Cymabay Therapeutics Inc (CBAY:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Gas prices are at a record high, and experts are forecasting that prices could go higher this summer — perhaps $5 or even over $6 a gallon. By clicking "TRY IT", I agree to receive newsletters and promotions from Money and its partners. I a...Stock Price Forecast The 1 analysts offering 12-month price forecasts for Creative Medical Technology Holdings Inc have a median target of 30.00, with a high estimate of 30.00 and a low estimate ...Future criteria checks 2/6. CymaBay Therapeutics is forecast to grow earnings and revenue by 47.6% and 61.6% per annum respectively. EPS is expected to grow by 45.7% per annum. Return on equity is forecast to be -57.1% in 3 years.Weather forecasts are essential tools for planning our daily activities, especially when it comes to the next 10 days. Understanding a weather 10 day forecast can help us make informed decisions about outdoor events, travel plans, or even w...

Cymabay Therapeutics 's revenue in 2023 is $31,016,000. On average, 7 Wall Street analysts forecast CBAY's revenue for 2023 to be $3,523,442,178, with the lowest CBAY …Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Digital Turbine Inc have a median target of 5.50, with a high estimate of 12.00 and a low estimate of 5.00. The median ...If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Being prepared to weather a hurricane — whether that involves fortifying your home or creating an emergency evacuation plan — is an important part of making it through the storm. Hurricanes travel across the ocean via massive, circular gust...Instagram:https://instagram. insurance for single maleqc event planningwhat trading platform does fidelity usehalf dollar is how much Nov 29, 2023 · Future criteria checks 2/6. CymaBay Therapeutics is forecast to grow earnings and revenue by 47.6% and 61.6% per annum respectively. EPS is expected to grow by 45.7% per annum. Return on equity is forecast to be -57.1% in 3 years. 3 year treasury note ratehome loans for bankruptcy The average Guardforce Ai Co stock price prediction forecasts a potential upside of 260.82% from the current GFAI share price of $3.88. What is GFAI's forecast return on assets (ROA) for 2023-2026? (NASDAQ: GFAI) forecast ROA is N/A, which is lower than the forecast US Security & Protection Services industry average of N/A. tsly ex dividend date 2023 CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline ...We’ve all flipped between different weather apps, wondering why each is giving a slightly different report. Before we look at AccuWeather, it’s important to understand the basics of weather forecasting. In the past, weather predictions were...